Zobrazeno 1 - 10 of 56 pro vyhledávání: '"J M Calvo Romero"'
2
[Extended anticoagulant treatment of venous thromboembolic disease with direct oral anticoagulants]
Autor: J M, Calvo Romero, E M, Lima Rodríguez
Publikováno v: Semergen. 44(7)
Direct oral anticoagulants have demonstrated efficacy and safety in the treatment of venous thromboembolic disease. A review is presented of the results of direct oral anticoagulants in the published clinical trials of extended anticoagulant treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::02f2b511b4eae1289cb6124795a234f9
https://pubmed.ncbi.nlm.nih.gov/30327093
Zobrazit plný text záznamu
3
Low-molecular-weight heparins in patients with atrial fibrillation
Autor: J M, Calvo Romero
Publikováno v: Revista clinica espanola. 217(3)
In clinical practice, low-molecular-weight heparins are used relatively frequently in patients with atrial fibrillation to prevent embolic events. In this article, it is revised the available evidence in the following clinical situations: rapid onset
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::514c5e22107328b8a8a86efed48a874e
https://pubmed.ncbi.nlm.nih.gov/28277238
Zobrazit plný text záznamu
4
Giant cell arteritis: diagnosis and treatment
Autor: J M, Calvo Romero
Publikováno v: Revista clinica espanola. 215(6)
Giant cell arteritis is the most common primary systemic vasculitis in adults. The condition is granulomatous arteritis of large and medium vessels, which occurs almost exclusively in patients aged 50 years or more. This article reviews the diagnosis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d71ec99c9af186b214e5d8044431f991
https://pubmed.ncbi.nlm.nih.gov/25957859
Zobrazit plný text záznamu
6
[New oral anticoagulants in the treatment of venous thromboembolic disease]
Autor: J M, Calvo Romero, E M, Lima Rodríguez
Publikováno v: Semergen. 39(3)
Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4761e0e281ebf1c2d203da867c9f4ddd
https://pubmed.ncbi.nlm.nih.gov/23540987
Zobrazit plný text záznamu
7
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?]
Autor: J M, Calvo Romero
Publikováno v: Revista clinica espanola. 211(3)
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiven
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8d5f3a55ee7e34ccdc1551368419db9e
https://pubmed.ncbi.nlm.nih.gov/21371701
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje